Myung-Lip Kim, CEO of Bilix “Pay attention to bilirubin scalability, targeting the global market”

Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water.

It is Bilix that solved this problem. Bilix succeeded in forming water-soluble nanoparticles by synthesizing non-toxic substances and bilirubin. Strategic investors (SI) and financial investors (FI), who recognized the growth potential, also stepped up to support Bilix. After attracting 14 billion won in Series A investment in the first half of this year, Billix plans to attract follow-up investment of up to 30 billion won next year.

CEO Myung-Lip Kim, has experience from start-up to medium-sized and large companies